An open-label, multicenter, randomized study Evaluating the efficacy and safety of glofitamab In combination with gemcitabine plus oxaliplatin Versus standard of care in patients with Relapsed/refractory large b-cell lymphoma

INTERVENTION: Experimental group:Glofitamab + Gemcitabine + Oxaliplatin;Control group:Standard salvage chemotherapy (like ICE, DHAP, etc.), and if remission is achieved, then continue with autologous stem cell transplant (ASCT); CONDITION: Relapsed or Refractory Large B‐Cell Lymphoma PRIMARY OUTCOME: Event‐Free Survival; SECONDARY OUTCOME: Objective Response Rate;Complete Response rate; INCLUSION CRITERIA: 1. Sign the informed consent form; 2. Be at least 18 years old when signing the informed consent form and willing to follow the study protocol; 3. Histologically confirmed LBCL; 4. Relapsed or refractory disease after first‐line immunochemotherapy: (1) Refractory disease is defined as not achieving complete remission with first‐line treatment; participants intolerant to first‐line treatment are excluded: 1) Best response to first‐line treatment is progressive disease (PD); 2) Best response is stable disease (SD) after at least 3‐4 cycles of first‐line treatment; 3) Best response is partial remission (PR) after at least 6‐8 cycles, or disease progression occurs within <=12 months of starting treatment; (2) Relapsed disease is defined as achieving complete remission with first‐line treatment, followed by biopsy‐confirmed relapse within <=12 months of starting first‐line treatment; 5. No known or suspected history of central nervous s